Pharmacokinetics of quinine in patients with chronic renal failure

✍ Scribed by P. Rimchala; J. Karbwang; K. Sukontason; V. Banmairuroi; P. Molunto; K. Na-Bangchang

• Publisher: Springer
• Year: 1996
• Tongue: English
• Weight: 521 KB
• Volume: 49
• Category: Article
• ISSN: 0031-6970
• DOI: 10.1007/bf00195937

✦ Synopsis

Methods: We investigated the pharmacokinetics of quinine (Qn) following administration of a single oral dose of 600 mg Qn sulphate in six male Thai patients with a moderate degree of chronic renal failure (CRF), and six male Thai subjects with normal renal function.

Results:

The drug was well tolerated in both groups of subjects; no major adverse reactions were observed. A marked alteration in the pharmacokinetics of Qn was found in patients with CRF compared to healthy subjects; there were six signifiicant changes in the pharmacokinetic parameters. Absorption was delayed, but increased in CRF (tmax 4.5 vs 1.6 h, Cm~x 6.17 vs 3.45 gg" ml-~). Total clearance was significantly reduced (0.94 vs 2.84 ml-rain-1. kg ~, whereas Vz/f remained unchanged (1.82 vs 2.78 1. kg-1). This resulted in the increased values of AUC and prolongation of the tl/zz and MRT in the patients (AUC 181.5 vs 61.8 gg' rain -1.mI 1, h/Zz 26 vs 9.7 h, MRT 36.4 vs 11.3 h). Median concentrations of plasma unbound fraction of Qn collected at 4 h after drug administration in patients and healthy subjects were 7.3 vs 9.8%, respectively.